Kaye Scholer - Notable Mandates

Notable Mandates

Transactional

• Represented Wind Point Partners in multiple acquisitions of consumer products companies, including certain assets of Consolidated Biscuit Company, and on the same day, the Cereal Division of Golden Temple of Oregon, LLC, a leading manufacturer and marketer of all-natural ready-to-eat cereals, bulk granola and granola snacks.
• Advised Essie Cosmetics in its agreement to be acquired by L'Oréal USA.
• Represented Sandoz in its agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company.
• Advised Jarden Corporation, a leading provider of niche consumer products used in and around the home, in multiple acquisitions, including its acquisition of the Mapa Spontex baby care and home care businesses of French conglomerate Total S.A.
• Represented ASP Westward, a portfolio company of American Securities, and publisher of 60 weekly and daily newspapers, in its acquisition of two East-Texas newspapers from Cox Enterprises Inc.
• Represented Parsons Brinckerhoff Inc. in connection with the merger agreement with Balfour Beatty plc.
• Advised WCI Steel along with Boston law firm McDermott Will & Emery in its acquisition by OAO Severstal in 2008, a transaction valued at $327 million.
• Represented Onex Corporation in its acquisition of the Health Group of Eastman Kodak Company for cash consideration of $2.35 billion in 2007.
• Counseled Onex Corporation in its acquisition of the Wichita/Tulsa division of Boeing Commercial Airplanes for consideration of $.9 billion in cash in 2005.
• Previously represented Onex Corporation and Oaktree Capital Management in their C$2 billion disposal of Loews Cineplex Entertainment Corporation to Bain Capital in 2004.
• Advised Chef America Inc. in its acquisition by Nestle SA for total consideration of $2.6 billion in cash and debt. The deal closed in October 2002.

Litigation

• Represented Wyeth in a landmark victory - Wyeth v. Kappos in January 2010, successfully challenging, at the district court level and on appeal, the U.S. Patent and Trademark Office’s interpretation of the statute designed to compensate patent holders for loss of patent term due to delays in processing applications.
• Successful defense of Pfizer in Viagra product liability litigation over the past decade; obtaining a long line of summary judgment decisions against claims of various diseases and ailments.
• Lead patent counsel for Pfizer in its patent infringement lawsuit against Teva Pharmaceuticals U.S.A., Inc. in which Teva attempted to bring a generic version of Celebrex to market.